EUVIMEDEUVIMED entdecken
LeitlinieÜbersichtsarbeitOpen Access · CC BY 4.0

Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use of 177Lu-PSMA-617 radioligand-therapy in prostate cancer

Ovidio Fernández Calvo, José Muñoz Iglesias, Estephany Abou Jokh Casas, Aura Molina-Díaz, Urbano Anido Herranz, Javier Casas Nebra, Lucía García-Bernardo, Sara Martínez-Breijo, Martín Lázaro-Quintela, Gloria Muñiz-García, Sergio Vázquez-Estevez

Clinical and Translational Oncology · 2024

DOI: 10.1007/s12094-024-03662-7 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von Ovidio Fernández Calvo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Complexo Hospitalario Universitario de Ourense, Ourense, Spain. ovidiofernandezcalvo@yahoo.es. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Dipeptides, Radiopharmaceuticals, Heterocyclic Compounds, 1-Ring. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Theragnostic is a type of precision medicine that uses molecules linked to radioactive isotopes for the diagnosis and treatment of diseases. In recent years, it has gained significant importance to treat neuroendocrine tumors and is currently being used in prostate cancer. Various radiopharmaceuticals have emerged for diagnosing and detecting lesions showing prostate-specific membrane antigen (PSMA) positivity on the Positron emission tomography/computed tomography scan, being the most widely used labeled with [ 68 Ga] and [ 18 F]. Its use as therapy in prostate cancer (PC) has been assessed in the VISION, TheraP, and PSMAfore clinical trials conducted with the radioligand [ 177 Lu]Lu-PSMA-617, demonstrating significant antitumor activity. The aim of this article is to present practical recommendations, based on current available scientific evidence and on a multidisciplinary consensus, for the diagnosis and treatment with [ 177 Lu]Lu-PSMA-617 in patients with PC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsDipeptidesRadiopharmaceuticalsHeterocyclic Compounds, 1-RingLutetiumHumansMaleNuclear MedicineSocieties, MedicalRadioisotopesProstate-Specific Antigen

Stichwörter der Autor:innen

Castration-resistant prostate cancerPSMARadioligandsRecommendationsTheragnostic

Substanzen

DipeptidesRadiopharmaceuticalsHeterocyclic Compounds, 1-RingLutetiumLutetium-177PSMA-617PluvictoRadioisotopesProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Medical Oncology, Complexo Hospitalario Universitario de Ourense, Ourense, Spain. ovidiofernandezcalvo@yahoo.es.
  • Department of Nuclear Medicine (SERGAS), University Hospital of Vigo, Meixoeiro Hospital, Vigo, Spain.
  • Department of Nuclear Medicine, Hospital Universitario Lucus Augusti, Lugo, Spain.
  • Department of Medical Oncology, Complexo Hospitalario Universitario de A Coruña, A Coruña, Spain.
  • Department of Medical Oncology, Complexo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain.
  • Uro-Oncology Unit, Complexo Hospitalario Universitario de A Coruña, A Coruña, Spain.

Zitieren

APA

Fernández Calvo, O., Muñoz Iglesias, J., Abou Jokh Casas, E., Molina-Díaz, A., Anido Herranz, U., Casas Nebra, J., García-Bernardo, L., Martínez-Breijo, S., Lázaro-Quintela, M., Muñiz-García, G., & Vázquez-Estevez, S. (2024). Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use of 177Lu-PSMA-617 radioligand-therapy in prostate cancer. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03662-7

Vancouver

Fernández Calvo O, Muñoz Iglesias J, Abou Jokh Casas E, Molina-Díaz A, Anido Herranz U, Casas Nebra J, et al. Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use of 177Lu-PSMA-617 radioligand-therapy in prostate cancer. Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03662-7

BibTeX
@article{FernndezCalvo2024,
  author = {Fernández Calvo, Ovidio and Muñoz Iglesias, José and Abou Jokh Casas, Estephany and Molina-Díaz, Aura and Anido Herranz, Urbano and Casas Nebra, Javier and García-Bernardo, Lucía and Martínez-Breijo, Sara and Lázaro-Quintela, Martín and Muñiz-García, Gloria and Vázquez-Estevez, Sergio},
  title = {Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use of 177Lu-PSMA-617 radioligand-therapy in prostate cancer},
  journal = {Clinical and Translational Oncology},
  year = {2024},
  doi = {10.1007/s12094-024-03662-7}
}
Kostenlos starten →